It is noteworthy, however, that, despite the effectiveness of aromatase inhibitors (AIs) in BC treatment in post-menopausal women, AIs develop endocrine resistance modulating cancer death [12,13,14]. This evidence concerns the gene CYP19A1 and breast cancer.